drugset / Trial / NCT01694810

Cutaneous Tolerability and Safety of NVN1000 Topical Gel in Healthy Volunteers

NCT01694810 ↗

Phase 1 Completed 60 enrolled Novan, Inc.
RandomizedParallel-groupSingle-blindTreatment

Summary

The study will assess safety and tolerability of different doses of topical gel containing a new chemical entity, NVN1000, and the vehicle (gel without drug) applied to the face of healthy volunteers with high counts of Propionibacterium acnes. The test product will be applied once daily for 4 weeks. Exploratory measures include whether the topical product decreases the amount of a bacteria associated with acne (P. acnes).

Timeline

Start
2012-09
Primary completion
2012-11
Completion
2012-11

Drugs

EvaluationDrugModalityDoseRoute
Subject BERDAZIMER SODIUM Small molecule 2 % Topical
Subject BERDAZIMER SODIUM Small molecule 4 % Topical
Subject BERDAZIMER SODIUM Small molecule 8 % Topical

Indications